Is Atai Beckley Inc. (ATAI) a Buy, Sell, or Hold?
Atai Beckley Inc.
NASDAQ:ATAI
$5.36 USD
-$0.31 (-5.47%)
- Volume
- 6.14M
- Average Volume
- 7.7M
- Market Capitalization
- $1.97B
- P/E Ratio
- -1.79
- Dividend Yield
- 0.00%
- Price Target
- $11.50
- Year High
- $6.75
- Year Low
- $2.59
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.02
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Srinivas G. Rao |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ATAI |
| CUSIP | 04650F101 |
| CIK | 0002081043 |
| Web | https://www.ataibeckley.com |
| Phone | 332 282 0507 |
| Currency | USD |
| Employees | 99 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 10.02 |
| Quick Ratio | 10.02 |
| Cash Ratio | 1.73 |
Sales & Book Value
| Annual Sales | $4.09M |
| Price / Sales | 565.76 |
| Cash Flow | -0.52 |
| Price / Cash Flow | -16.84 |
| Price / Book | 6.11 |
Price Target and Rating
| Average Stock Price Forecast | $11.50 |
| High Stock Price Forecast | $17.00 |
| Low Stock Price Forecast | $10.00 |
| Forecast Upside/Downside | -53.39% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 5 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.91 |
| Trailing P/E Ratio | -1.79 |
| PEG Ratio | 0.01 |
| P/E Growth | 0.01 |
| Net Income | $-660.05M |
| Net Margin | -19019.44% |
| Pretax Margin | -19018.90% |
| Return on Equity | -366.49% |
| Return on Assets | -250.46% |
Financials Score
| AltmanZ Score | 3.64 |
| Piotroski Score | 4.00 |
| Working Capital | 225.1M |
| Total Assets | 264.88M |
| Ebit | -663.12M |
| Market Cap | 2.01B |
| Total Liabilities | 66.1M |
Poll Results
About Atai Beckley Inc. (NASDAQ:ATAI) Stock
Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada. Its development pipeline features several key compounds: BPL-003: An intranasally administered formulation of mebufotenin benzoate salt, currently undergoing Phase 2a and 2b clinical trials for its potential in treating both treatment-resistant depression (TRD) and alcohol use disorder. RL-007: An orally active, pro-cognitive neuromodulator, progressing through a Phase 2b study focused on cognitive impairment associated with schizophrenia. ELE-101: A serotonergic psychedelic compound designed to address ... major depressive disorder. VLS-01: An oral transmucosal film featuring N,N-Dimethyltryptamine, which is in a Phase 2 clinical study for TRD. EMP-01: An orally administered form of R-3,4-methylenedioxy-methamphetamine, also in Phase 2 trials for social anxiety disorder. EGX-A & EGX-B: Non-hallucinogenic 5-HT2A receptor agonists, which are being explored for treatment-resistant depression. Beyond these pipeline assets, the firm also provides COMP360 for psilocybin therapy and GRX-917, aimed at treating anxiety, depression, and various neurological conditions. Originally known as Atai Beckley N.V., the entity officially changed its name to Atai Beckley Inc. in December 2025. Established in 2018, its corporate headquarters are situated in New York, New York.
Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley, Bloomberg News reports
2026-07-15 19:08:30
Eli Lilly is in talks to acquire psychedelic drugmaker AtaiBeckley , and a deal could be announced as soon as this week, Bloomberg News reported on Wednesday, citing people familiar with the matter.
Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies
2026-07-15 11:34:00
Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could...
Is AtaiBeckley Inc (ATAI) Stock Outpacing Its Medical Peers This Year?
2026-07-14 10:40:17
Here is how AtaiBeckley Inc (ATAI) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
CleanSpark shares surge after company secures $6.6B data center lease agreement
2026-07-14 07:53:00
CleanSpark Inc (NASDAQ:CLSK) shares surged more than 12% after the company announced a 20-year lease agreement for its Sandersville, Georgia data center...
2026-07-14 07:20:00
Tower Semiconductor (NASDAQ:TSEM) shares rose 13% on Tuesday after the company announced a strategic expansion of its silicon photonics, silicon germanium...
Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says
2026-07-13 15:18:27
The US Food and Drug Administration's finalized guidance on psychedelic drug development signals the agency remains receptive to helping developers navigate the approval process, a development that Jefferies said could benefit companies including Compass Pathways (NASDAQ:CMPS), AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Cybin Inc. (NYSE-A:CYBN, FRA:R7E), GH Research (NASDAQ:GHRS), Awakn Life Sciences (NEO:AWKN) and others in the sector. The firm wrote on Monday that the final guidance, alongside the FDA's plans to hold a public hearing on September 14, points to a more supportive regulatory environment that could reduce regulatory risk for psychedelic drug developers.
What This $496,000 Insider Sale at AtaiBeckley Means Amid Roughly 100% Stock Run
2026-07-09 19:52:13
This disposal of 100,000 shares was executed at $4.96 per share, generating gross proceeds of $496,000 on July 7, 2026. The transaction reduced Hershberg direct equity position by 50% through the sale of shares in the open market.
FuelCell Energy shares fall after company prices upsized $225M stock offering
2026-07-08 07:51:00
FuelCell Energy (NASDAQ:FCEL) shares declined on Wednesday after the company priced an upsized public offering of common stock, raising concerns among...
Frequently Asked Questions
-
What is the current Atai Beckley Inc. (ATAI) stock price?
-
Atai Beckley Inc.(NASDAQ:ATAI) stock price is $5.36 in the last trading session. During the trading session, ATAI stock reached the peak price of $6.75 while $2.59 was the lowest point it dropped to. The percentage change in ATAI stock occurred in the recent session was --5.47% while the dollar amount for the price change in ATAI stock was -$-0.31.
-
ATAI's industry and sector of operation?
-
The NASDAQ listed ATAI is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ATAI?
-
Christian Angermayer | Co-Founder & Chairman of the Board
Anne Johnson | Chief Accounting Officer
Kavita Panke | Senior Vice President of New Product, Planning & Commercial
Kevin Craig | Chief Medical Officer
Robert Conley | Chief Research & Development Officer -
How many employees does ATAI have?
-
Number of ATAI employees currently stands at 99. ATAI operates from 250 West 34th Street, New York, NY 10119, US.
-
Link for ATAI official website?
-
Official Website of ATAI is: https://www.ataibeckley.com
-
How do I contact ATAI?
-
ATAI could be contacted at phone #332 282 0507 and can also be accessed through its website. ATAI operates from 250 West 34th Street, New York, NY 10119, US.
-
How many shares of ATAI are traded daily?
-
The average number of ATAI shares traded daily for last 3 months was 7.7M.
-
What is the market cap of ATAI currently?
-
The market value of ATAI currently stands at $1.97B with its latest stock price at $5.36